How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?

References

• Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614–625.
   PubMedGoogle Scholar
• Gratwohl A, Pasquini MC, Aljurf M, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e 91–100.
   Web of Science ®Google Scholar
• Shenoy S, Angelucci E, Arnold SD, et al. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23:552–561.
   PubMed Web of Science ®Google Scholar
• Germing U, Schroeder T, Kaivers J, et al. Novel therapies in low- and high-risk myelodysplastic syndrome. Expert Rev Hematol. 2019;12:893–908.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther. 2016;10:465–481.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kontoghiorghe CN. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology. Expert Opin Investig Drugs. 2019;28:593–603.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. New targeted therapies and diagnostic methods for iron overload diseases. Front Biosci (Schol Ed). 2018;10:1–20.
   PubMedGoogle Scholar
• Papakonstantinou O, Alexopoulou E, Economopoulos N, et al. Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia major. J Magn Reson Imaging. 2009;29:853–859.
   PubMed Web of Science ®Google Scholar
• Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci. 2005;1054:373–378.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassaemia after bone-marrow transplantation. Lancet. 1993;342(8884):1388–1391.
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329:840–844.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. Chelation protocols for the elimination and prevention of iron overload in thalassaemia. Front Biosci (Landmark Ed). 2018;23:1082–1098.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin. 2011;35:186–198.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Pilo F. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Ann N Y Acad Sci. 2016;1368:115–121.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Lucarelli G, et al. Treatment of iron overload in the “ex-thalassemic”. Report from the phlebotomy program. Ann N Y Acad Sci. 1998; 850:288–293.
   Google Scholar
• Pullarkat V. Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol. 2010;2010:pii: 345756.
   PubMedGoogle Scholar
• Cremers EMP, de Witte T, de Wreede L, et al. A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019;60:2404–2414.
   PubMed Web of Science ®Google Scholar
• Vallejo C, Batlle M, Vázquez L, et al. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica. 2014;99:1632–1637.
   PubMed Web of Science ®Google Scholar
• Jaekel N, Lieder K, Albrecht S, et al. Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:89–95.
   PubMedGoogle Scholar
• Maximova N, Gregori M, Simeone R, et al. Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility’s five years’ experience of chelation treatment. Oncotarget. 2017;8:63177–63186.
   PubMedGoogle Scholar
• Vill K, Müller-Felber W, Teusch V, et al. Proximal muscular atrophy and weakness: an unusual adverse effect of deferasirox iron chelation therapy. Neuromuscul Disord. 2016;26:322–325.
   PubMed Web of Science ®Google Scholar
• Schmid H, Jelkmann W. Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs. 2016;25:901–916.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 2019;133:790–794.
   PubMed Web of Science ®Google Scholar
• Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. Blood. 2019;133:1279–1289.
   PubMed Web of Science ®Google Scholar
• Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol. 1996;51:243–244.
   PubMed Web of Science ®Google Scholar
• Chang YH, Shaw CF, Wu KH, et al. Treatment with deferiprone for iron overload alleviates bone marrow failure in a Fanconi anemia patient. Hemoglobin. 2009;33:346–351.
   PubMed Web of Science ®Google Scholar
• Visani G, Guiducci B, Giardini C, et al. Deferasirox improves hematopoiesis after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:585–587.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The history of Deferiprone (L1) and the paradigm of the complete treatment of iron overload in thalassaemia. Mediterr J Hematol Infect Dis. 2020;12:e2020011.
   PubMed Web of Science ®Google Scholar